source
- Caribou Biosciences halts pipeline and announces major workforce cutCaribou Biosciences, a Bay Area biotech that develops off-the-shelf CAR-T cell therapies, said it will stop all clinical development and begin a substantial workforce reduction. The company, which…
- ArriVent’s phase 3 EGFR inhibitor trial misses primary endpoint, shares plunge 57%ArriVent BioPharma reported results from its phase 3 Furvent trial, which evaluated firmonertinib, a brain-penetrant EGFR inhibitor, in patients with exon 20 insertion-mutated non-small cell lung c…